DNA Genetic Tests: Warfarin Dose Prediction
  • Required only hours from blood sample to results
  • Designed for easy operation & analysis
  • Validated accuracy with 400+ patients samples* & DNA sequencing
  • Protected by US, Europe, and world wide patents
  • CE Marked IVD Kit
 image1

Many studies have demonstrated the important role of genetic variability of vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes in determining the dose of warfarin that should be used when the oral anticoagulant is initiated. Individuals that use DNA tests to determine their genotypes of these two genes can use the test results with other information to reach quickly a stable therapeutic dose while reducing drug adverse reactions at the same time. (visit WarfarinDosing.org)

Table 1: Warfarin Dosage Related SNP typing
Genomic DNA
Samples
VKORC1
-1639(G>A)
CYP2C9*3
c.1075(A>C)
CYP2C9*2
c.430(C>T)
Ethnicity of Health Volunteers
 
GG
GA
AA
AA
AC
CC
CC
CT
TT
Caucasian
100
38
48
14
87
12
1
67
32
1
Chinese Han
100
1
19
80
90
10
0
100
0
0
Asian
246
35
78
133
231
14
1
242
4
0
Total
446
74
145
227
408
36
2
409
36
1

VKORC1 (-1639 G>A) Test
  • VKORC1 TaqMan Detection MixMix
  • PCR Master Mix (2x conc.)
  • Positive Control Templates
    • GG
    • GA
    • AA


Workflow
VKORC1

 

  
CYP2C9*2 (c.430 C>T) Test
  • CYP2C9*2 TaqMan Detection Mix
  • PCR Master Mix (2x conc.)
  • Positive Control Templates
    • CC
    • CT
    • TT


Workflow
CYP2C9*2

 

  
CYP2C9*3 (c.1075 A>C) Test
  • CYP2C9*3 TaqMan Detection Mix
  • PCR Master Mix (2x conc.)
  • Positive Control Templates
    • AA
    • AC
    • CC


Workflow
CYP2C9*3